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Abstract
Introduction The under-reporting of adverse drug events
(ADEs) is an international health concern. A number of
studies have assessed the root causes but, to our knowl-
edge, little information exists relating under-reporting to
practices and systems used for the recording and tracking
of drug-related adverse event observations in ambulatory
settings, institutional settings, and retail pharmacies.
Objectives Our objective was to explore the process for
reporting ADEs in US hospitals, ambulatory settings, and
retail pharmacies; to explore gaps and inconsistencies in
the reporting process; and to identify the causes of under-
reporting ADEs in these settings.
Methods The Tufts Center for the Study of Drug Devel-
opment (Tufts CSDD) interviewed 11 thought leaders and
conducted a survey between May and August 2014 among
US-based healthcare providers (HCPs) in diverse settings
to assess their experiences with, and processes for,
reporting ADEs.
Results A total of 123 individuals completed the survey
(42 % were pharmacists; 27 % were nurses; 15 % were
physicians; and 16 % were classified as ‘other’). HCPs
indicated that the main reasons for under-reporting were
difficulty in determining the cause of the ADE, given that
most patients receive multiple therapies simultaneously
(66 % of respondents); that HCPs lack sufficient time to
report ADEs (63 % of respondents); poor integration of
ADE-reporting systems (53 % of respondents); and uncer-
tainty about reporting procedures (52 % of respondents).
Discussion The results of this pilot study identify that key
factors contributing to the under-reporting of ADEs relate to a
lack of standardized process, a lack of training and education,
and a lack of integrated health information technologies.
Key Points
This pilot study evaluated adverse drug event (ADE)
reporting processes in US hospitals, private
practices, and retail pharmacies.
The results highlight gaps in the reporting process
that fall into three categories: technology, education,
and the overall process.
Recommendations include integrating health
information systems to streamline the reporting
process, training and educating both healthcare
providers and patients on ADE reporting, and
creating a standardized ADE-reporting process.
1 Introduction
Adverse drug events (ADEs)—defined by the World
Health Organization (WHO) as ‘‘a response to a medicine
which is noxious and unintended, and which occurs at
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doses normally used in man’’ [1]—are extremely costly to
society. For example, half of all ADEs in the USA are the
result of preventable medication errors; they affect more
than 7 million patients, cause 7000 deaths, and cost more
than $US20 billion across all care settings each year [2–4].
When a drug is approved, its efficacy and safety is
accepted with the expectation that its benefit–risk profile
will be further expanded by exposure to more patients in
real-world healthcare settings, some of whom may have
been excluded from registrational study enrollment. In the
USA, this passive post-approval monitoring system relies
on voluntary and accurate reporting that identifies a pro-
duct and its manufacturer [5–7]. The majority of ADE
reports are sent directly to drug manufacturers; some are
sent directly to the US FDA via its MedWatch program.
The FDA’s Sentinel Initiative is another source of admin-
istrative and claims-based data that enables the study of
real-world effects of a medication [8, 9].
Following the launch of a drug, the FDA requires bio-
pharmaceutical companies to report any and all sponta-
neous ADEs once an event has been observed and the
patient, observer, and suspect product identified [10]. Other
regulatory agencies have similar programs: the European
Medicines Agency’s EudraVigilance is the European
equivalent.
Standardized reporting systems with ongoing institution-
based surveillance have assisted healthcare providers
(HCPs) in voluntarily reporting ADE observations and
complying with regulatory guidance. ADE reports have led
to drugs being withdrawn from the market because of risks
outweighing benefits [6]. However, a number of studies
indicate that the under-reporting of ADEs is a pervasive
and widespread problem [6, 11–18]. For example, two
studies noted that the FDA receives reports for less than
1 % of suspected serious ADEs [8, 19].
In 2015, the results of a study by Ma et al. [20] sug-
gested that some pharmaceutical organizations and manu-
facturers add to the under-reporting issue by delaying
reports of serious ADEs. Their study indicated that roughly
10 % of all serious ADEs were not reported to the FDA
within the 15-day required time period. The study con-
cluded that one possible explanation was that pharmaceu-
tical companies could be taking longer to investigate the
reports; however, they concluded, ‘‘this discretion is out-
side the scope of the current regulatory regime.’’ [20].
In the USA, ADE reporting to the FDA or manufacturer
is voluntary. However, policies around ADEs are created
and decided upon at the state level. For example, some
states require pharmacists to report vaccine ADEs. As of
January 2008, 26 states had created regulations related to
hospital adverse event (AE) reporting, and one had recently
decided to create policies [21]. Although roughly half of
the states had systems in place, under-reporting was still
considered a large problem in 2010 [11, 22]. It remained a
considerable issue in 2012; the Office of the Inspector
General had seen no improvements in reporting, noting that
hospitals were still recording only 1 % of ADEs and that,
although 60 % of ADEs occurred in hospitals with
infrastructure in place for reporting, only 12 % of ADEs
were reported by hospitals with such infrastructure [23].
Although some hospitals have implemented technology
systems to capture ADEs, the quality of the data are
questionable as misclassification of an ADE for a given
drug in a multisource market is prevalent. Krahn et al. [17]
discussed a European project, SALUS (Scalable, Stan-
dard based Interoperability Framework for Sustainable
Proactive Post Market Safety Studies), and tools and
algorithms that assess a patient’s electronic health record
(EHR)/electronic medical record (EMR) and notify physi-
cians of any possible ADEs. They noted that the algorithms
were only as strong as the data entered by individual HCPs,
which was a limitation of the project [17]. Elliott et al. [16]
evaluated an electronic clinical safety reporting system
implemented in Newfoundland and Labrador, Canada, and
noted an increase in the number of ADEs reported with the
use of this tool by hospital staff (i.e., not physicians or
nurses). However, they also noted that challenges with
customizing the tool increased the time it took to report an
event [16]. Klein et al. [24] looked at the traceability of
biological medicines in the Netherlands and concluded that
deficiencies in the systematic capture of biological drug
brand names and lot (batch) numbers for ADE reporting
could be due to ‘‘shortcomings in the recording of infor-
mation in clinical practice.’’ Studies conducted by the Tufts
Center for the Study of Drug Development (Tufts CSDD)
[25] and by Vermeer and colleagues [26, 27] also
demonstrated that the quality and completeness of volun-
tary ADE reporting results in misclassification and an
inability to trace observations to the source or suspect
product.
Several studies have assessed the root causes of under-
reporting. Varallo et al. [15] conducted a systematic review
and concluded that the main causes for under-reporting
included William Howard Wallace Inman’s description,
‘‘ignorance, insecurity, and indifference.’’ Goldman et al.
[28] investigated pediatric ADEs and observed that inclu-
sion of a drug safety service resulted in a fourfold increase
in reporting. Hirose et al. [29] found that signal detection
time, i.e., lag time, was longer for physicians reporting
ADEs than for nurses. However, Pagotto et al. [14] noted
that primary educational interventions in Europe increased
both the number and the quality of ADE reports. However,
in the USA, while studies indicate that hospitals are still
under-reporting, few have focused on why that under-re-
porting occurs [14, 15] and, specifically, the process for
reporting ADEs and the gaps in that process.
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In 2014, under an unrestricted grant from Amgen Inc.,
we conducted a two-part study to explore the process for
reporting ADEs in US hospitals, ambulatory settings, and
retail pharmacies; to explore the gaps and inconsistencies
in the reporting process; and to further identify reasons for
under-reporting of ADEs in these settings. We hope the
results of this study will inform policy makers on best
practices for ADE reporting.
2 Methodology
In January 2014, Tufts CSDD first conducted a literature
review to map the ADE-reporting process and to identify
any known gaps within that process. From February to May
2014, Tufts CSDD interviewed 11 thought leaders to gain
insight into the systems and technologies supporting each
step in the process. Individuals interviewed were claims
data experts, pharmacists, and physicians and from the
FDA and generics manufacturing companies.
Based on the interview findings, Tufts CSDD created a
data-collection instrument (i.e., survey) assessing the
ADE-reporting process in hospitals (i.e., institutional),
ambulatory (i.e., private practice), and retail pharmacy
settings. Survey respondents were asked about the
following:
• their experience in healthcare and reporting ADEs;
• the process for reporting AEs at their primary treatment
setting;
• thoughts on the reasons for ADEs not being reported;
• health information systems used for ADE reporting.
To assess the ADE-reporting process, respondents were
provided 10–18 possible steps in the ADE-reporting pro-
cess, depending on professional setting. Respondents
selected and ordered the steps to create a reporting process
map. Using a Likert scale, respondents then reported
whether the selected steps were consistently completed at
their institution. Respondents employed by hospitals were
provided 18 possible steps to select and order, respondents
in private practice were provided 13 possible steps, and
respondents employed by retail pharmacies were provided
14. The complete survey questionnaire may be found in the
Electronic Supplementary Material.
Data were analyzed using descriptive statistics. Group
comparisons were conducted using the Chi-squared test for
independence (alpha level 0.05). Qualitative responses
were coded and categorized into main themes.
The survey was sent to individuals in internal and
external databases via e-mail, social media, and HCP and
pharmacist associations from three states: New Jersey,
New York, and Washington. The number of individuals
who received an invitation to participate is unknown, as the
HCP and pharmacist associations did not disclose the total
number of individuals in their associations. The survey was
conducted from 16 May 2014 to 31 August 2014.
3 Results
3.1 Phase I
Tufts CSDD conducted 11 interviews with thought leaders
in pharmacovigilance. One individual had worked in the
Office of Surveillance and Epidemiology at the FDA, one
individual worked for a generics manufacturer, three were
professors of epidemiology with expertise in claims data;
the remaining six were pharmacists or physicians in an
ambulatory setting, a retail pharmacy setting, or an insti-
tutional setting.
Interviewees indicated that many health information
technology (HIT) systems are typically used. Table 1 lists
the HIT systems found in a typical US hospital and a
definition of each.
The systems listed in Table 1 were also in place in
ambulatory settings. Employees in such a setting also relied
on the pharmacy’s Patient Medication Record (PMR)
system, which forwards patient diagnoses to health insur-
ance companies. A PMR captures patient information,
medication prescription information (dose, quantity,
name), dispenser of the medication, and prescriber infor-
mation [35]. Interviewees noted that the incident-reporting
systems were not integrated with any of the other electronic
systems (e.g. computerized physician order entry [CPOE],
EHR/EMR), and that the incident reporting systems did not
have a feature that could push ADE data directly to the
FDA or drug manufacturer.
3.2 Phase II
3.2.1 Respondent Demographics and Adverse Drug Event
(ADE) Reporting History
Of the 284 respondents who participated, 123 completed
the survey (47 worked in hospitals, 31 in ambulatory set-
tings, 14 in retail pharmacies, and 31 in other, e.g., medical
professionals employed by correction facilities, senior
centers, the military, school systems, etc.). The survey
outreach design described in the methodology meant the
majority of respondents who completed the survey worked
in New Jersey, New York, and Washington State. Table 2
contains their demographic information.
The majority (51 %) of the 123 respondents who com-
pleted the survey had not reported any ADEs to the FDA or
drug manufacturer in the last 5 years. There was a statis-
tically significant difference in the number of times an
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ADE had been reported by occupation; pharmacists had
reported one or more ADEs more often than nurses or
physicians (p = 0.005; Chi-squared test for independence).
Table 3 shows the percentage breakdown by occupation
and number of times an ADE was reported in the last
5 years.
Of respondents who reported an ADE in the last 5 years,
92 % had reported to two or more organizations. The main
organizations reported to were as follows: internal report-
ing, FDA MedWatch, and the drug manufacturer. Phar-
macists reported ADEs internally and to FDA MedWatch
more often than either physicians or nurses (p\ 0.0001
and p = 0.002, respectively, Chi-squared test for inde-
pendence). Table 4 provides a percentage breakdown of
where ADEs were reported by occupation.
By setting, of the respondents who selected internal
reporting, 61 % worked in a hospital, 18 % in an ambu-
latory setting, 6 % in a retail pharmacy, and 15 % else-
where (p = 0.0001, Chi-squared test for independence).
3.2.2 ADE Reporting Process Flow
Among all respondents, no single ADE-reporting process
dominated. However, although not in the same order, six
steps were identified as being a part of the ADE-reporting
process by all parties across treatment settings. Figure 1
depicts the common elements in the process for reporting
an ADE across all settings, along with the main gaps
identified for four of the six steps in the ADE-reporting
process.
After determining the ADE-reporting process within
their organization, respondents determined how consis-
tently each selected step was performed. ‘‘Reporting the
ADE’’ was often one of the least consistent steps in the
process across all treatment settings. Table 5 highlights the
most and least consistent steps in the process by setting.
Within the hospital setting, 44 % of respondents
(n = 75) were unsure whether a formal procedure for
reviewing reports submitted to incident reporting existed,
Table 1 Health information technology systems within a typical hospital practice. Phase IV post-marketing clinical trials are also used to track
and report adverse drug events if the hospital is taking part in an established post-marketing study
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ADE adverse drug event, HCP healthcare provider, ICD-9 International Classification of diseases and related health problems, ninth revision,
WHO World Health Organization
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22 % indicated no formal procedure existed, and 34 %
indicated a formal procedure was in place.
3.2.3 Parties Accountable for ADE Reporting
When respondents were asked who was accountable for
reporting ADEs, 33 % of those from a hospital or institu-
tional setting, 20 % from an ambulatory or private practice,
and 36 % from a retail pharmacy were uncertain.
Of those from a hospital or institutional setting, 36 %
retail pharmacy; 33 % unsure, 11 % risk-mitigation
department, 20 % indicated ‘other’. When stratifying by
occupation, there was less clarity on who was responsible
for reporting ADEs: 45 % of pharmacists stated the phar-
macist was responsible for reporting, but only 21 % of
nurses and 38 % of physicians agreed with this (n = 75; all
respondents, not only those who completed the entire
survey).
Table 2 Survey demographics
Demographic Pharmacists Nurses Physicians Other HCP Total
Setting
Hospital/institutional 32 (26) 15 (12) 0 (0) 0 (0) 47 (38)
Ambulatory/private practice 0 (0) 4 (3) 18 (15) 9 (7) 31 (25)
Retail pharmacy 11 (9) 0 (0) 0 (0) 3 (2) 14 (11)
Other 9 (7) 14 (11) 1 (1) 7 (6) 31 (25)
Total 52 (42) 33 (27) 19 (15) 19 (15) 123a
State
NJ 0 (0) 29 (24) 0 (0) 10 (8) 39 (32)
NY 24 (20) 0 (0) 13 (11) 4 (3) 41 (33)
WA 21 (17) 0 (0) 0 (0) 0 (0) 21 (17)
Other 7 (6) 4 (3) 6 (5) 5 (4) 22 (18)
Total 52 (42) 33 (27) 19 (15) 19 (15) 123a
From NJ From NY From WA From other Total
Setting
Hospital/institutional 12 (10) 20 (16) 7 (6) 8 (7) 47 (38)
Ambulatory/private practice 10 (8) 13 (11) 0 (0) 8 (7) 31 (25)
Retail pharmacy 0 (0) 4 (3) 8 (7) 2 (2) 14 (11)
Other 17 (14) 4 (3) 6 (5) 4 (3) 31 (25)
Total 39 (32) 41 (33) 21 (17) 22 (18) 123a
Data are presented as N (%) unless otherwise indicated
HCP healthcare provider, NJ New Jersey, NY New York, WA Washington
a Reflects only respondents who completed the survey. Individuals in the ‘other’ category are employed by institutions such as correction
facilities, senior centers, academic/school systems, and the military
Table 3 Frequency of adverse
drug events reported to the FDA
or the drug manufacturer in the
last 5 years by occupation
Occupation ADEs reported to the FDA/drug manufacturer p value (Chi-squared)
None 1–4 times C5 times
Physician 63 32 5 0.005
Nurse 68 27 5
Pharmacist 33 48 19
Overall 51 38 11
Data are presented as % unless otherwise stated
Chi-squared test for independence, alpha level 0.05; sample size is 123 respondents (those who completed
the survey)
ADE adverse drug event
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Of those from an ambulatory or private practice setting,
20 % were unsure, 27 % indicated the physician, and 20 %
indicated the nurse was responsible for reporting ADEs. By
occupation, there was less clarity on who was responsible
for reporting ADEs in this setting: 47 % of physicians
stated the physician was responsible for reporting, but only
6 % (n = 30) of nurses agreed with this.
Of those from a retail pharmacy setting, five of 14
indicated the pharmacy manager, four indicated the staff
pharmacist, and five answered ‘other’.
3.2.4 Potential Reasons for the Under-Reporting of ADEs
Figure 1 shows the main gaps associated with each main
step in the process:
• The patient did not report the ADE to the HCP or
pharmacist.
• HIT did not consistently capture drug manufacturer,
National Drug Code (NDC) number, and lot number of
the drug.
• HCPs did not have enough time to gather all the
required information.
• HCPs were unclear about when to report and who was
responsible for reporting.
Figure 2 contains respondents’ perceptions on why
HCPs may not have reported ADEs to the FDA or drug
manufacturer. The top three reasons were that the patient
was receiving more than one therapy so it was difficult to
establish which drug caused the ADE (66 % of respondents
selected ‘often’ or ‘very often’); that [the HCP] did not
have enough time to devote to reporting given the priority
placed on the provision of care (63 % of respondents
selected ‘often’ or ‘very often’); and that integration
between the disparate electronic systems and the reporting
Table 4 Organization to which
respondent has reported an
adverse drug event, by
occupation
Pharmacist Nurse Physician Total p value
Sample size (n) 52 44 19 115
Agency reported to
Internal Reporting 75 45 21 55 \0.0001
FDA MedWatch program 58 25 26 40 0.002
Drug manufacturer 42 20 26 31 0.06
State Department of Health 6 14 11 10 0.42
State Board of Pharmacy 8 7 0 6 0.47
Never reported an ADE 8 34 42 23 0.001
Data are presented as % unless otherwise indicated
Chi-squared test for independence, alpha level 0.05; sample size is 115 respondents (the total number of
respondents answering the question, e.g., a total of 44 nurses answered the question, whereas only 33
completed the entire survey)
ADE adverse drug event
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- Lack of me to gather 
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Fig. 1 Process flow and main gaps identified for adverse drug event reporting across all settings. ADE adverse drug event, HCP healthcare
provider, MFR manufacturer, NDC National Drug Code, PS primary suspect
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form is lacking (53 % of respondents selected ‘often’ or
‘very often’).
Overall, respondent perceptions were consistent across
the three different settings; however, the following
exceptions were noted:
• 76 % of respondents employed in hospitals selected
‘often/very often’ for not having enough time, com-
pared with 47 % of respondents in an ambulatory
setting and 60 % of respondents in a retail pharmacy
(p = 0.005; Chi-squared test for independence).
Table 5 Most and least consistent steps in the adverse drug event reporting process, stratified by setting
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 On more than one therapy, so diﬃcult to establish which drug
caused ADE.
Does not have enough me to devote to reporng  given priority on
provision of care.
Lack integraon between the disparate electronic systems and the
reporng form.
Unsure about reporng procedure.
Unsure about whom to report to.
Does not report ADE to health care provider.
Diﬃcult to establish that the event is caused by a drug.
Unaware of the beneﬁts of reporng.
Does not bring in the drug, so diﬃcult to ﬁll out drug-related
reporng informaon.
Lack paent’s prescripon history.
Oen/Very Oen Rarely/Somemes Unsure
Fig. 2 Respondent perceptions on reasons preventing health care providers from reporting adverse drug events to the FDA or to the drug
manufacturer. Sample size is 173, all respondents answering the question. ADE adverse drug event
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• 93 % of respondents employed in a retail pharmacy
selected ‘often/very often’ for [patient] does not report
ADE to healthcare provider, compared with 40 % of
respondents employed in a hospital and 37 % of
respondents employed in an ambulatory setting
(p = 0.005; Chi-squared test for independence).
• 72 % of respondents employed in an ambulatory setting
selected ‘rarely/sometimes’ for being unaware of the
benefits of reporting, compared with 43 % of respon-
dents employed in a hospital and 60 % of respondents
employed in a retail pharmacy (p = 0.03; Chi-squared
test for independence).
3.2.5 Gaps in Health Information Technology Solutions
When respondents employed in hospital or institutional
settings were asked about what HIT could be accessed to
retrieve details about the suspect drug to aid in reporting the
ADE, respondents selected an average of 3.2 sources (range
1–7); 46 % gathered data from four or more sources.
Respondents indicated an average of 2.6 sources fromwhich
to retrieve details about the ADE, with 51 % of respondents
selecting three or more sources for ADE details.
However, not all electronic systems contained all relevant
information. Hospital electronic systems did not routinely
capture manufacturer information, NDC, drug expiry date
and lot number. Table 6 lists the percentage of respondents
from a hospital setting that stated key variables useful for
identifying specific products and batches (e.g., for complex
and sensitive products such as biologics) were available
within a specific hospital electronic system. No hospital
electronic system routinely captured manufacturer, expiry
date, lot number, and NDC, which are used as US product
identifiers in the International Organization for Standard-
ization’s Identification of Medicinal Products (ISO IDMP).
Respondents relying on paper-based systems exhibited a
similar trend when asked about data capture. NDC and lot
numbers were never (11 of 25 respondents) or rarely (13 of
25) captured, whereas active ingredient and brand was
often (14 of 25) or always (12 of 25) captured.
Of the 30 respondents from an ambulatory or private
practice setting, 27 indicated at least one electronic system
was available at their private practice. When asked about
electronic systems available to track and report ADEs, only
five of 23 respondents with an EHR system indicated it
could be used to track ADEs. None of the respondents had
one-click forward ADE to the drug manufacturer capabil-
ity. When asked about services allowing access to infor-
mation about a patient’s medication history, 17 % of
respondents from this setting were aware of or subscribed
to such a service; 63 % were not aware of such a service.
Seven of 14 respondents from retail pharmacies indi-
cated no tracking system was in place for recording ADEs.
Respondents also indicated that electronic systems lack the
ability to record the active ingredient and lot number: three
and four of 14 respondents, respectively, indicated that the
active ingredient and lot number were available in the
patient’s profile.
4 Discussion
This Tufts CSDD study examined the process for reporting
ADEs in US hospitals, private practice, and retail phar-
macies and identified factors contributing to ADE under-
Table 6 Availability of
variables required for adverse
drug reporting by the main
hospital electronic system
Variables to identify suspect products EHR/EMR CPOE eMAR BCMA BCMP IR
Sample size (n) 57 57 59 38 23 33
Dose 95 95 98 95 91 85
Administration route 96 93 97 89 78 88
Label strength 86 82 86 82 87 79
Brand name 82 81 81 76 74 76
Active ingredient 53 60 54 50 43 55
Concomitant medications 67 63 61 39 35 33
Manufacturer 23 14 15 34 70 30
NDC 28 18 15 37 52 27
Expiry date 19 14 15 29 57 27
Lot number 14 9 10 16 39 27
Data are presented as % unless otherwise indicated
Sample size is 59 respondents employed in a hospital setting
ADE adverse drug event, BCMA Barcode-enabled Medication Administration, BCMP Bar-Code Medica-
tion Preparation Technologies, CPOE Computerized Physician Order Entry system, EHR electronic health
record, eMAR Electronic Medication Administration Record, EMR electronic medical record, IR electronic
incident reporting system, NDC National Drug Code
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reporting. Survey results indicate that pharmacists, pre-
dominantly those in a hospital setting, have the most
experience reporting ADEs compared with physicians and
nurses. Across all settings, factors for not reporting ADEs
could be classified into three categories:
• Gaps in technology integration was lacking between
disparate electronic systems and the reporting process
form (53 % of respondents selected this ‘often/very
often’ prevented HCPs from reporting ADEs to the
FDA or drug manufacturer). Additionally, the patient
often did not bring drug packaging, making it difficult
to complete drug-related reporting information (38 %
of respondents). Lastly, patients’ prescription history
was lacking (31 % of respondents).
• Gaps in education there were reported gaps in educa-
tion around ADEs and the ADE-reporting process.
Examples of gaps in education around ADEs include
how to establish which drug caused the ADE when the
patient is receiving more than one therapy (66 %) and
how to establish that the event was caused by a drug
(47 %). Examples of gaps in education around the
ADE-reporting process include that respondents were
unsure about reporting procedures (52 %) and to whom
the report should be made (51 %) and that respondents
were unaware of the benefits of reporting (39 %).
• Gaps in process respondents indicated they did not
have time to devote to reporting given the priority
placed on provision of care (63 %) and that patients did
not report the ADE to the HCP (48 %).
HCPs indicated the main reason for not reporting ADEs
is that the patient typically receives more than one therapy,
making it difficult to establish which drug caused the ADE,
followed by not having enough time to report given the
priority placed on provision of care. Respondents also
indicate a lack of integration between electronic systems
within the hospital and that they are not sure about the
reporting process or to whom the report should be made.
To some extent, difficulty in identifying a primary sus-
pect drug is an intrinsic limitation of the ADE-reporting
system, but the other major obstacles identified in the
survey involve extrinsic factors that may be open to
improvement. Suggestions for improving ADE reporting
involve improving integration between electronic systems,
simplifying the reporting process, and increasing aware-
ness of the benefits of reporting.
Although respondents indicated the inability to deter-
mine which drug caused the ADE and lack of integration in
HIT are the main gaps, there is no set process for hospitals
and private practices to follow. This lack of standardized
process could explain why 52 % of respondents are unsure
about the reporting process and 51 % are unsure about to
whom they should report. Moreover, it may explain why
33 % of respondents in a hospital setting and 20 % of those
in private practice indicated they were uncertain about who
is responsible for ADE reporting. Those who were certain
about who is responsible could provide no consensus as to
who was accountable: physician, nurse, or pharmacist. This
could be partly because the FDA and professional associ-
ations such as the American Medical Association and
American Pharmacists Association have not offered guid-
ance on best practices for voluntary ADE reporting. While
27 states have regulations covering hospital ADE report-
ing, each state’s regulations may vary, which will make the
creation of a standard operating procedure more challeng-
ing. For example, Levinson [21] noted that key differences
existed in the definitions of a reportable event, the report-
ing procedure for the ADE, and other requirements for
submission.
This study corroborates the findings of Varallo et al.
[15] that the lack of education within both hospital and
ambulatory settings is noteworthy. In addition to not being
familiar with the overall process for reporting ADEs and
the benefits of reporting, respondents were unclear as how
to determine which therapy caused the ADE or whether the
event was even established by a drug. These concepts can
be addressed in training and continuing education. How-
ever, there are two targetable intervention groups: the
reporter (physician, nurse, pharmacists) and the patient.
Pagotto et al. [14] demonstrated that training sessions and
education increased ADE reporting in European hospitals,
and—through separate patient and healthcare provider
surveys—Yi et al. [36] noted that patients would prefer
education and training on ADEs from their physician,
followed by their pharmacist. However, in the HCP survey,
physicians indicated they were not likely to educate
patients on ADEs. Thus, a lack of education may play a
large role in ADE under-reporting.
Not having enough time to devote to reporting, given
priorities placed on the provision of care, was the second
most common reason selected by HCPs for not reporting
ADEs. The third reason was lack of integration between
different HITs. Key details are spread among multiple data
sources: 46 % of respondents (N = 74) indicated that drug
details were spread across four or more sources and 51 %
(N = 69) indicated that ADE details are spread across
three or more sources. Moreover, Table 6 indicates that
details important for ADE reporting—manufacturer, NDC,
expiry date, and lot number—are not commonly found in
EHR, CPOE, eMAR (Electronic Medication Administra-
tion Record), or BCMA (Barcode-enabled Medication
Administration). These drug details may be especially
important for complex or sensitive medications, such as
biologics, for which it may be important to link AEs to
specific manufacturers and lot numbers [25, 27]. Thus,
integration of and improvements in access to information
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are needed to streamline the reporting process. One sug-
gestion would be to integrate product-specific data from
barcode-based systems into other HIT systems to improve
the availability of drug–data elements currently missing in
other systems. Table 7 contains recommendations for
improving ADE reporting.
The current Tufts CSDD study has some limitations and
biases. This study had a small sample size of 123 HCPs
completing the survey and so may not be generalizable. The
majority of hospital-based survey responses originated from
three US states (New York, New Jersey, Washington).
These three states have regulations related to mandatory
hospital reporting of AEs [21, 22]. The findings of this study
may not be generalizable to states that do not have regu-
lations in place. Additionally, 23 % (n = 52) of hospital
respondents had never reported an ADE (internally or
externally) and 48 % had never reported an ADE to the
FDA or a manufacturer. Individuals who have not reported
an ADE may be less aware of the process than those who
have, thereby skewing some of the results. Additionally,
while physicians in a hospital setting started the study, none
completed it, suggesting that physician perceptions were
not captured for questions later in the survey. Additionally,
this study was cross-sectional and used a survey tool;
therefore, no causal inferences can be made. Lastly, the
survey did not assess reporting requirements for near mis-
ses; i.e., an event that could have resulted in injury due to
medication error and not due to an ADE, and what should be
done to report near misses to the FDA. Future directions and
steps will attempt to address these limitations by expanding
the study to more geographic regions as well as furthering
our understanding of the root causes of ADE under-re-
porting and assessing the types of training and education
systems within hospitals and private practices.
In 1976, William Howard Wallace Inman identified
seven ‘‘deadly sins’’ for ADE under-reporting: compla-
cency; fear of litigation; guilt from incorrect prescribing;
ambition to publish a case study; ignorance of the process;
insecurity about reporting suspicions (diffidence); and
indifference in role of sharing medical knowledge [15, 37].
Now, 40 years later, all sins still apply but two particularly
stand out: ignorance of process and insecurity about accu-
rately identifying the drug causing the ADE. As such, not
only should improvements be made in HIT to streamline the
reporting process but stakeholders such as regulatory
agencies and associations should also provide stronger
guidance and continuing training for HCPs to increase
awareness of both the importance of reporting events and
the processes that should be followed in each setting.
5 Conclusion
This Tufts CSDD pilot study evaluated the process for
ADE reporting in hospitals (i.e., institutional settings),
private practice (i.e., ambulatory settings), and retail
pharmacies. Tufts CSDD administered a survey to physi-
cians, nurses, and pharmacists to determine the overall
process and gaps in ADE reporting. These gaps fell into
three areas: technology, education, and the overall process.
Recommendations include integrating HIT systems to
streamline the reporting process, training and education for
both HCPs and patients on ADE reporting, and creation of
a standardized ADE reporting process.
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